Behind the Markets is a monthly stock picking and investing newsletter led by Dylan Jovine.

As part of a 2024 promotion, Dylan claims to have identified a small, publicly-traded biotech company on the verge of discovering a revolutionary treatment for Alzheimer’s, Parkinson’s, and dementia.

By subscribing to Behind the Markets today, you get the name and ticker symbol of that company along with a bundle of bonus reports.

Keep reading to discover everything you need to know about Behind the Markets today in our review.

What is Behind the Markets?

Behind the Markets is the flagship newsletter from the financial publishing company Behind the Markets.

Behind the Markets is priced at $49 to $99 per year and provides investment research, stock picks, and analysis across multiple industries.

The goal of Behind the Markets is to identify companies whose stocks are selling at a significant discount compared to what their underlying business is worth, according to Dylan Jovine’s research. Dylan aims to help his followers earn steady, long-term growth by consistently identifying these companies.

While other stock-picking newsletters focus on get-rich-quick-style investing, Behind the Markets takes a different approach. Behind the Markets is designed for conservative investors seeking long-term value, focusing mostly on mid-cap and medium-term investment opportunities across all sectors.

Behind the Markets: Market-Beating Returns, Guaranteed!

Behind the Markets Benefits

Some of the benefits of your Behind the Markets include:

• Stock picks, market analysis, and more in each monthly newsletter
• Discover the biotech company seeking to cure Alzheimer’s, Parkinson’s, and dementia
• Access to Behind the Markets portfolio and positions
• Trade alerts
• 24/7 access to members-only portal
• 30-day, 100% money-back guarantee

The Behind the Markets Investment Philosophy

Dylan Jovine designed Behind the Markets with a simple premise: to identify undervalued companies and invest in those companies.

Key pillars of Behind the Markets’ investment philosophy include:

• Provide investment research on companies whose stocks are selling for a significant discount
• It is ideal for conservative investors seeking long-term value
• Available across all market sectors
• Focus on mid-cap, medium-term investment opportunities (typically focusing on companies with market capitalizations between $1 billion and $10 billion)
• Use a business valuation approach that seeks to provide small investors with a significant advantage over large investors
• Identify companies with high returns on equity, low debt, and a durable competitive advantage

Larger investors tend to invest based on modern portfolio theory. They’re risk-averse and seek average returns over the long run. Behind the Markets seeks a different approach to identify growing companies undervalued based on their current stock price.

Of course, every good investor seeks to identify undervalued companies. It’s part of buying low and selling high. What makes Behind the Markets different?

Dylan Jovine and his team often focus specifically on companies that have recently experienced a temporary setback, sending the price of their stock down to reasonable price levels. If Dylan’s predictions are correct, this setback is temporary, and the company will continue growing long-term, allowing investors to maximize returns.

Don’t Miss Out! Biotech Breakthroughs Unveiled—Subscribe to Behind the Markets!

Are We Nearing “The End of Alzheimer’s”?

As part of a 2024 promotion for Behind the Markets, Dylan Jovine and his team have launched a promotion heralding “The End of Alzheimer’s.”

Dylan has identified a small biotech company seeking to cure Alzheimer’s, Parkinson’s, and dementia.

By subscribing to Behind the Markets today, you will receive immediate access to a bonus report explaining the company’s name and ticker symbol and why Dylan believes it’s worth an investment.

Although we can’t spoil complete details about the company upfront, here are some of the most important things to know about it:

• The biotech company is a small, publicly traded firm seeking to fight Alzheimer’s, Parkinson’s, and dementia. If they’re successful, their treatment could be “the end of Alzheimer’s” and other degenerative brain conditions.
• Jeff Bezos and other notable names have already backed the biotech company. According to Dylan Jovine, Jeff Bezos invested $130 million in the company.
• One big pharmaceutical giant recently purchased an 11.2% stake in the firm. Biogen, Sanofi, and Genentech, meanwhile, recently paid over $1 billion to license their treatment from this company.
• The biotech company is developing an unconventional treatment for degenerative brain disease. If successful, this treatment would help tens of millions of people.
• That unconventional treatment method is related to a “drug smuggler” method, although Dylan provides limited information about this drug smuggler approach upfront.
• The Economist describes the treatment as a “boon to humanity,” while The Wall Street Journal claims “The financial benefits would be massive” if the firm is successful. Jim Cramer, meanwhile, describes the treatment as “the biggest drug ever.”

Dylan sees the small biotech company as an excellent investment opportunity for all of these reasons and more. He claims it “has the potential to do more than just make you rich.”

Click here to learn more about Behind the Markets!

Who is Dylan Jovine?

Dylan Jovine is the CEO and founder of Behind the Markets, a financial publishing company.

Dylan and his company publish multiple newsletters, including the flagship newsletter, Behind the Markets. Other newsletters include Biotech Insider, Breakthrough Wealth, Hidden Market Profits, and Takeover Targets.

Before leading a financial publishing company, Dylan Jovine had spent decades working in finance.

Dylan started his career on Wall Street in 1991 after ” growing up poor and attending a city college.” Because of his background, Dylan was turned down by big hedge funds like JP Morgan and Goldman Sachs. Dylan started working with Peter Jacquith, an investment banker who became famous for saving New York City from bankruptcy in the 1970s (and later became homeless and addicted to drugs before recovering in the early 2000s).

In his early career, Dylan built a reputation for picking stocks before they were taken over. Dylan was in his early 20s, but he had a proven track record of recommending companies that were about to soar in price because of a takeover.

In 1996, when Dylan was 24, one of his clients bankrolled him to start his brokerage firm. He became one of the youngest in US history to launch a registered broker-dealer and market maker, operating the firm from 100 Wall Street.

Dylan enhanced his reputation during the 2008 recession. For example, he claims to have predicted the recession one year before it took place. Then, during the recession, he earned massive returns on a handful of investments.

In 2013, Dylan became sick after 20+ years of making money for clients. Although he revealed limited information about his illness upfront, it forced him to leave the industry.

Today, Dylan uses his decades of experience to share investment opportunities through Behind the Markets. Behind the Markets offers a range of newsletters, including its flagship advisory service, Behind the Markets, to help investors earn market-beating returns by picking the right stocks.

Dylan Jovine’s Stock Picks: Your Path to Long-Term Growth. Subscribe Now!

The 3 Pillars of Biotech Investing

Biotech investing is one of the best ways for investors to make market-beating returns.

If you pick the right biotech company today, before the public hears about a dramatic new treatment, you could earn huge returns.

Many of Dylan Jovine’s recommended investments are in the biotech space – including his latest recommendation, the small biotech company making an Alzheimer’s treatment.

Dylan uses specific criteria to make smarter biotech investments. Here are Dylan’s three pillars of biotech investing:

• Ingredient #1: Breakthrough Science: Dylan Jovine focuses on companies with breakthrough science. They need a team of “breakthrough scientists” capable of creating that breakthrough science. A team of scientists who can consistently identify areas of the industry where others haven’t gone puts the company ahead of its competitors. Dylan’s recommended Alzheimer’s company, for example, is led by the former Head of Neuroscience at a major pharmaceutical company, which is why he believes in the small biotech firm.
• Ingredient #2: Massive Market: Degenerative brain disease is one of the world’s leading causes of death. It affects tens of millions of people worldwide each year. It’s a massive market. You could create the biggest drug in the world, but that drug won’t be a smart investment if it only cures ten people. Instead, Dylan aims to identify biotech companies working on larger solutions. The biotech company identified by Dylan Jovine, for example, is working on a drug that could save the United States $20 trillion.
• Ingredient #3: Distribution Partner: Most biotech companies are run by scientists and academics. That’s why the best biotech companies work with businesspeople, logistics specialists, and distribution partners who understand the business side. Dylan claims the distribution partner is “by far the rarest and most special” part of identifying a biotech company. However, it’s the difference between the great biotech investments and the cream of the crop opportunities.

See for yourself why Behind the Markets is so popular >>>

Why Alzheimer’s Drugs Are a Big Investment Opportunity

Dylan Jovine believes one biotech company fits all three pillars mentioned above, making it a great investment opportunity.

He also likes that the company is focusing specifically on Alzheimer’s, Parkinson’s, and other degenerative brain diseases.

Here are some of the reasons Dylan believes Alzheimer’s drugs are a big investment opportunity:

It Costs $27,672 Per Year to Treat One Patient with Alzheimer’s: Alzheimer’s drugs cost around $2,306 per month, or $27,672 per year. Patients are already spending tens of thousands of dollars on ineffective Alzheimer’s drug treatments.

Americans Spend $20 Trillion (Including $15 Trillion in Public Healthcare Funds) on Alzheimer’s Each Year): If we extrapolate the number above to America’s population with Alzheimer’s, we discover it costs Americans $20 trillion per year to treat Alzheimer’s – including $15 trillion in Medicaid and Medicare expenses.

Big Pharma Sells an Estimated $16 Billion Worth of Alzheimer’s Drugs Each Year: Big pharmaceutical companies sell $16 billion worth of Alzheimer’s drugs each year to help manage symptoms of Alzheimer’s and slow the progression of the disease.

Today’s Alzheimer’s Drugs Don’t Work Because They Can’t Reach the Brain: Despite selling billions of dollars worth of Alzheimer’s drugs each year, today’s Alzheimer’s drugs aren’t very effective because they can’t cross the blood-brain barrier. Your brain has a natural barrier that large molecules cannot cross, limiting the effectiveness of brain drugs.

Drugs that Treat Alzheimer’s Could Treat Other Brain Diseases: The same drugs that treat Alzheimer’s could also treat Parkinson’s, dementia, and other degenerative brain diseases. If a company could create an effective solution for crossing the blood-brain barrier, it would be a major pharmaceutical breakthrough.

The Neurodegenerative Disease Drug Market is Estimated at $62.7 Billion: 15.8 million people in the United States live with neurodegenerative disease. Analysts expect this market to be worth $62.7 billion by 2026.

For all of these reasons and more, Dylan Jovine sees a big opportunity in the biotech space—particularly in Alzheimer’s disease. That’s why he’s confident that a small biotech company could be a great investment.

Expert Biotech Insights: Behind the Markets Has You Covered!

Previous Biotech Winners from Behind the Markets

Dylan Jovine and his team at Behind the Markets are confident about their new recommended biotech company.

Why? The company has spotted previous opportunities and recommended biotech companies to investors at huge returns.

Since retiring in 2018, Dylan Jovine claims to have “helped folks make money buying into unknown biotech stocks before the rest of the world knew about them.”

Some of Dylan’s winning biotech stocks have included:

• ChemoCentrix, which rose 435% after Dylan recommended buying it
• Krystal Biotech, which rose 275%
• Array Biopharma, which rose 144%
• Kura Oncology, which rose 124%
• Tesaro, which rose 93%
• Loxo Oncology, which rose 78%

However, Dylan believes his newly identified biotech company could be even bigger than these opportunities, creating even larger returns for investors:

“As remarkable as these gains are…They don’t compare to what’s in front of us right now…If you were to make only one investment in the next decade, this is it. It doesn’t get clearer than this.”

Many of Dylan’s recommended biotech companies have soared in value after an acquisition. Even if Dylan’s identified biotech company gets bought out, he’s confident investors will make a strong return on investment.

Unlock Hidden Gems with Behind the Markets. Subscribe Today!

What’s Included with Behind the Markets?

As part of a 2024 promotion, all new subscriptions to Behind the Markets come with a bundle of bonus reports, investment guides, and more – including one guide listing the name and ticker symbol of the Alzheimer’s drug developer mentioned above.

Here’s what you get when you subscribe to Behind the Markets today:

1. Monthly Issues of Behind the Markets: Subscribers receive a new issue of Behind the Markets each month. Each issue features a minimum of one stock recommendation along with market analysis, portfolio updates, and more. Dylan focuses on companies with market capitalizations between $1 billion and $10 billion, aiming to invest for a medium-term length of time. Many recommended companies have recently experienced a temporary setback, allowing investors to get in at a discount rate for better long-term value accumulation. The goal is to provide conservative investors with long-term growth and value.
2. Access to Model Portfolio: All Behind the Markets subscribers get access to a model portfolio packed with Dylan’s previous recommendations. The portfolio includes the stocks Dylan has previously recommended buying, including his entry points and target exit points.
3. Regularly Updates & Trade Alerts: When Dylan spots a major change in one of his model portfolio stocks, he alerts subscribers. For example, if he believes it’s time to sell or buy more, he may issue an alert between monthly issues of Behind the Markets.
4. 24/7 Access to Members-Only Website: All Behind the Markets subscribers get access to a members-only platform. This platform lets you see Behind the Markets’ previous issues, access a report library, check the model portfolio, and more.
5. Free Bonus Report #1: Past the Blood-Brain Barrier: The Small Company Revolutionizing Alzheimer’s Disease: Modern Alzheimer’s drugs struggle to get past the BBB or blood-brain barrier. It’s a natural barrier that prevents large molecules from entering your brain. Dylan Jovine has spotted one small biotech company that may have developed a solution to crossing the blood-brain barrier. Major pharmaceutical companies and investors like Jeff Bezos have already invested in the company. It has the potential to change the future of Alzheimer’s, Parkinson’s, and dementia treatment. This report features the name and ticker symbol of the company and why Dylan believes it’s a smart investment.
6. Free Bonus Report #2: Bullet-Proof: How to Create the Ideal Small-Cap Biotech Stock Portfolio: Dylan is a big fan of small-cap biotech stocks. He has earned triple-digit returns on multiple biotech stocks over the last decade. In this guide, you can discover Dylan’s recommendations for creating an ideal small-cap biotech stock portfolio. The guide teaches you, in the words of Dylan, “how to contrast a bullet-proof biotech portfolio with tremendous upside…that could make you filthy rich.” People who finish reading this report are “well on your way to earning life-changing profits in biotech.”
7. Free Bonus Report #3: Herbert Royalties: How to Collect Entertainment Royalties While You Sleep: Dylan Jovine is a big fan of using a unique royalty investment method to collect entertainment dollars as you sleep. It used to be that only rich and famous people could collect royalties. Today, however, there’s a way for any ordinary investor to tap into a pool of growing royalties. In this report, you can discover exactly how this system works – and how to get a piece of the “royalty bonanza” in less than five minutes.
8. Free Bonus Report #4: 3 Ingredients to Great Biotech Stocks: Dylan expands on the three biotech investing pillars mentioned above in this report. He teaches you how to pick great biotech investments by looking at groundbreaking science, strong distribution, and a large target market. Dylan has used these three pillars to make multiple strong investments in biotech over the years, and he’s confident it can help others earn huge returns.
9. Free Bonus #5: Tidal Wave Profits: How the Medical Revolution Will Change Your Relationship with Your Doctor: Today’s best biotech companies are changing the world of medicine. In this guide, you can discover how a new generation of medicine is treating prostate cancer, a step-by-step guide to how biological treatments are making old chemical treatments a thing of the past, and how ordinary investors can profit from all this.
10. Free Bonus #6: Income Collapse: How to Buck the Trend and Boost Your Monthly Income with New Investments: In this guide, normally valued at $179, Dylan explains how anyone can earn a steady income through various investment strategies. With dividend stocks and bonds difficult to predict, Dylan claims “retirees have virtually no play to go for income.” That’s why he recommends implementing his system to double your monthly income. His system aims to generate “target returns of 7% – 15% per year.”
11. Free Bonus Report #7: 6 Questions to Ask Before Buying Any Stock: You should ask certain questions before buying any stock. Whether investing in biotech or big tech, these questions can separate winners from losers. Some companies talk a big game but fail to live up to the hype. Other companies have good ideas but lack the infrastructure, technology, or management to bring those ideas to fruition. In this guide, you can discover the best stocks by asking six questions.

Overall, your subscription to Behind the Markets includes the core monthly issues and seven bonus reports, helping you maximize your chances of being a successful investor in biotech and other spaces.

This is the best time to order and get bonuses!

Behind the Markets Pricing

Behind the Markets is available at three subscription tiers: Good Offer, Great Offer, and Best Offer.

As part of a 2024 promotion, the Best Offer subscription is priced at the same rate as the Great Offer but comes with all seven bonus reports.

Here’s how pricing works when subscribing to Behind the Markets today:

Good Offer ($49 Per Year)

• Immediate access to Behind the Markets investment advisory service
• Access to a library of complimentary reports

Great Offer ($99 Per Year)

• Immediate access to Behind the Markets investment advisory service
• Free Bonus Report: Past the Blood-Brain-Barrier: The Small Company Revolutionizing Alzheimer’s Disease
• Free Bonus Report: 3 Ingredients to Great Biotech Stocks
• Free Bonus Report: 6 Questions to Ask Before Buying Any Stock

Best Offer ($99 Per Year)

• Immediate access to Behind the Markets investment advisory service
• Free Bonus Report: Past the Blood-Brain-Barrier: The Small Company Revolutionizing Alzheimer’s Disease
• Free Bonus Report: 3 Ingredients to Great Biotech Stocks
• Free Bonus Report: 6 Questions to Ask Before Buying Any Stock
• Free Bonus Report: ‘Medical Money’ – How to Create the Idea Small Cap Biotech Portfolio
• Free Bonus Report: ‘Biotech Income’ – How to Generate Monthly Income from Your Biotech Portfolio
• Free Bonus Report: ‘Pot Stocks’ – What the History of Cigarettes Tells Us About Cannabis
• Free Bonus Report: ‘Tidal Wave Profits’ – How the Medical Revolution Will Change Your Relationship With Your Doctor

Visit the official website to get discounted prices!

All subscriptions also come with the perks mentioned above, including access to the model portfolio and the members-only platform.

Behind the Markets Refund Policy

All Behind the Markets subscriptions come with a 30-day money-back guarantee. You have 30 days to try the subscription, read the bonus reports and guides, and request a refund if you’re unhappy.

As a thank you for trying Behind the Markets, you can keep all the digital bonuses you received. You don’t need to return anything to qualify for a refund.

About Behind the Markets

Behind the Markets is a financial publishing company led by Dylan Jovine. After working on Wall Street for 20+ years, Dylan decided to share his knowledge with the world via Behind the Markets.

Today, Behind the Markets offers five monthly advisory services: its flagship service, Behind the Markets, Biotech Insider, Takeover Targets, Breakthrough Wealth, and Hidden Market Profits.

You can contact Behind the Markets and the company’s customer service team via the following:

• Online Form: https://behindthemarkets.com/contact-us/
• Phone: 1-800-851-1965
• Mailing Address: 4260 NW 1st Avenue, Suite #55, Boca Raton, FL 33431-4264

Customer service is available on Monday to Friday from 10 am to 7 pm EST.

Final Word

Dylan Jovine and his team at Behind the Markets have launched a new promotional campaign for their flagship advisory service.

Each month, Dylan and his team send subscribers new stock recommendations, market analysis, and portfolio updates via a monthly newsletter. Subscribers also get access to a model portfolio, a members-only online platform, and other perks.

As part of a 2024 promotion, all new subscriptions to Behind the Markets come with a bundle of bonus reports—including one report featuring a small biotech company developing a treatment for Alzheimer’s. After subscribing, you get the name and ticker symbol of this company.

To learn more about Behind the Markets or to subscribe today, visit the official website.